Hep B eAg Inhibitors
Hep B eAg Inhibitors belong to a distinct chemical class of compounds specifically designed to target and interact with the Hepatitis B e Antigen (HBeAg). HBeAg is a viral protein that is produced by the Hepatitis B virus during active infection. The inhibitors are carefully formulated to disrupt the function or expression of HBeAg without affecting other viral components or cellular processes. These inhibitors are developed through extensive research and molecular modeling, utilizing the knowledge of the structure and function of HBeAg.
By selectively interfering with the activity of this antigen, Hep B eAg inhibitors aim to modulate the viral replication cycle and potentially affect the progression of Hepatitis B infection. Their mode of action may involve binding to specific regions of the HBeAg molecule or interfering with the formation of functional viral particles. Hep B eAg inhibitors hold significant promise in advancing our understanding of Hepatitis B viral dynamics and may open new avenues for further research in the field of virology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tenofovir | 147127-20-6 | sc-204335 sc-204335A | 10 mg 50 mg | $157.00 $646.00 | 11 | |
Similar to TDF, TAF is also a reverse transcriptase inhibitor used in the research of chronic hepatitis B. It has the advantage of being associated with less bone and renal toxicity compared to TDF. | ||||||
Telbivudine | 3424-98-4 | sc-222340 sc-222340A | 10 mg 100 mg | $138.00 $1092.00 | 1 | |
Telbivudine is an nucleoside analogue that interferes with viral DNA synthesis, inhibiting HBV replication. | ||||||
Adefovir dipivoxil | 142340-99-6 | sc-207260 sc-207260A | 50 mg 100 mg | $102.00 $251.00 | ||
Adefovir dipivoxil (CAS 142340-99-6) is a nucleotide analogue that functions as an inhibitor of the Hepatitis B e antigen (HBeAg) protein. It interferes with viral replication by targeting the reverse transcriptase enzyme, leading to chain termination during the replication process. This inhibition disrupts the synthesis and expression of HBeAg, making it useful for research studies focused on understanding viral protein mechanisms and replication pathways in Hepatitis B research. | ||||||
Lamivudine | 134678-17-4 | sc-221830 sc-221830A | 10 mg 50 mg | $104.00 $218.00 | 1 | |
Lamivudine is an nucleoside analogue that inhibits HBV DNA polymerase, reducing viral replication. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Lonafarnib is a farnesyltransferase inhibitor that has demonstrated HBeAg-reducing effects in studies. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
While traditionally used for cholesterol management, simvastatin has shown potential as an HBeAg inhibitor in research research. | ||||||